Advances and considerations in AD tau-targeted immunotherapy
The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to identify therapeutic targets that are causally involved in the disease process. However, accumulating evidence from experimental and clinical studies that investigate the early disease process point towar...
Main Authors: | Alice Bittar, Nemil Bhatt, Rakez Kayed |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-02-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996119303821 |
Similar Items
-
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
by: Castillo-Carranza DL, et al.
Published: (2013-12-01) -
“Tau immunotherapy: Hopes and hindrances”
by: Koorosh Shahpasand, et al.
Published: (2018-02-01) -
Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
by: Josef Marksteiner, et al.
Published: (2022-09-01) -
Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice
by: Chun-ling Dai, et al.
Published: (2018-01-01) -
Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
by: Linda J. Van Eldik, et al.
Published: (2024-10-01)